Cardiovascular safety of anti-CGRP monoclonal antibodies in older adults with migraine

Clinical impact: Results support the CV safety of anti-CGRP monoclonal antibodies in older adults or adults with disabilities who have migraines, providing reassurance for their use in this population, which is often underrepresented in clinical trials.

Study details: This retrospective, sequential cohort study analyzed Medicare claims data from May 2018 to December 2020, including 9,153 beneficiaries aged 18 or older with migraine who initiated either anti-CGRP monoclonal antibodies or onabotulinumtoxinA. Patients with a history of MI, stroke, cluster headache, malignancy, or hospice service within a year before treatment were excluded.

Results: No significant difference was observed in the incidence of MI or stroke between patients who initiated anti-CGRP monoclonal antibodies and those who used onabotulinumtoxinA. Findings suggests that anti-CGRP monoclonal antibodies don't elevate CVD risk compared with onabotulinumtoxinA among Medicare beneficiaries with migraine.

Source:

Yang S, et al. (2025, January 6). JAMA Neurol. Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine. https://pubmed.ncbi.nlm.nih.gov/39761027/